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Edited by Varda RotterAbstract To identify genes that are stimulated by oncogenic
forms of mutant p53, we studied, by microarray analysis and
PCR-select subtractive hybridization, gene expression changes in
human wild-type (wt) p53-negative immortal 041 ﬁbroblasts
infected to stably express p53 mutant 175H. In contrast to the wt
p53 transactivator, 175H induced only few and weak, gene
expression changes. We report here the stimulation of calmod-
ulin 2 (CaM 2), but not CaM 1 or 3, gene expression speciﬁcally
in 041 cells. The stimulation of the CaM 2 promoter required the
50 untranslated sequences as well as the integrity of the
transactivation domain of 175H. However, direct binding of
175H to the 50UT in vitro could not be demonstrated.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Oncogene expression and a large number of stresses that
disrupt the nucleolus can cause cell senescence or apoptosis
through the stabilization and activation of the p53 transcrip-
tion factor [1,2]. These tumor suppressive cellular responses are
themselves suppressed in many tumors by the mutational in-
activation of wt p53. Numerous observations have documented
that many full-length mutant forms of p53 are not only de-
fective for the wt functions but exert novel oncogenic activities
such as the increase of tumorigenicity [3], mutation frequency
[4], metastatic potential [5], and genomic instability [6,7]. It is
unclear precisely how mutant p53 acts as an oncoprotein but
several observations indicate that it may be able to regulate
genes despite of its defective core DNA binding domain [8–11].
Calmodulin (CaM) is a small ubiquitous calcium-binding
protein and a principal transducer of calcium signals that
modulates a large number of essential cellular processes in-
cluding cell motility and proliferation [12]. How can a single
protein be spatially and temporally regulated to orchestrate so
many, and sometimes even opposing, signals? One explanation
may be found in the unique feature of genetic redundancy
within the calmodulin gene family: Three CaM genes located
on diﬀerent chromosomes exhibit 20% divergency in their
coding regions, yet no amino acid substitutions; thus, all three
genes encode the same protein. By contrast, the non-coding
regions including the regulatory sequences of the three genes* Corresponding author. Fax: +49-6841-1623980.
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doi:10.1016/j.febslet.2004.05.052are very diﬀerent; nonetheless, each is highly conserved across
vertebrate species. Based on these and further observations, a
current model suggests that the local availability of CaM may
be regulated through the build-up of local CaM pools from
individual, diﬀerentially regulated CaM genes [13]. We report
here that p53 mutant 175H can stimulate speciﬁcally calmod-
ulin 2 (CaM 2), but not CaM 1 or 3, gene expression.2. Materials and methods
2.1. Cell culture, viruses and transfection
041, H1299 and Saos-2 cells were cultured in DMEM, supplemented
with 10% FCS and grown in a humidiﬁed 7% CO2 atmosphere at 37
C. Retroviruses were harvested from the 293GP producer lines as
previously described [14]. Cells were infected with titered virus stock in
the presence of 4 lg/ml polybrene (Sigma) for 4 h, and virus-infected
cells were selected in 400 lg/ml G418 at 48 h after infection for ap-
proximately seven days. For transient transfection, exponentially
growing cells in 12-well dishes were incubated for 4 h with 0.3 lg of
total DNA, of which 0.1 lg was empty vector, 0.1 lg was the green
ﬂuorescence protein expressing plasmid pEGFP-C3 (Clontech, Palo
Alto, USA), and 0.1 lg was either wild-type or mutant p53-expressing
plasmid (pCMV-wtp53, pCMV-175H, pCMV-175HDC, pCMV-
175H22,23, pCMV-175HDC22,23, pCMV-175HDO), or empty vector
(pCMVpA). As luciferase reporter plasmids either pGL2-Basic(CaM2-
luc), pGL2-Basic(CaM2-(D50UT)-luc) or pWaf-luc were employed. In
Southwestern analyses, reporter plasmid PG13-CAT containing 13
p53-binding sites and plasmid MG15-CAT with 15 mutated sites, were
additionally used. As transfection reagent, eﬀectene from Qiagen
(Hilden, Germany) was employed according to the manufacturer’s
recommendation for 12-well dishes. Luciferase assays were employed
using the ‘‘Luciferase Assay System’’ (Promega, Mannheim, Germany)
as speciﬁed by the manufacturer.2.2. Antibodies and immunoblot analysis
The p53 monoclonal antibody DO-1 was purchased from Calbio-
chem (San Diego, USA); the Calmodulin monoclonal antibody AB-2
(2D1) was from Neomarkers (Fremont, USA), and the monoclonal -
actin antibody was from Sigma–Aldrich (Taufkirchen, Germany).
Cells from 10 cm dishes were lysed in 150 ll of a lysis buﬀer heated to
85 C and containing 50 mM Tris–HCl (pH 6.8), 100 mM DTT, 2%
SDS and 20% glycerol. Samples containing 15 lg of total cellular
protein were subjected to 12% SDS–PAGE and transferred to a PVDF
membrane (Immobilon-P, Millipore, Bedford, USA). Signals were
detected upon overnight incubation of the membranes with anti-p53
(1:1000), anti--actin (1:5000), or anti-calmodulin (1:500) antibodies
followed by a ﬁnal incubation with a peroxidase-conjugated secondary
anti-mouse antibody and Renaissance Enhanced Luminol Reagents
(NEN, Boston, USA), performed as speciﬁed by the supplier.2.3. Northern and Southern blot analysis
Total RNA from cells grown on 10 cm dishes was isolated via
RNeasy Mini Kit from Qiagen (Hilden, Germany) as speciﬁed by the
supplier. 10 lg of DNaseI digested RNA (DnaseI: Roche, Mannheim,
Germany) was electrophoresed on a formaldehyde-containing 1%blished by Elsevier B.V. All rights reserved.
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blotted onto a nylon membrane (SS Nytran, Schleicher Schuell,
Germany) following standard procedures. The membranes were hy-
bridized with AlkPhos-labelled probes (Amersham Biosciences, Frei-
burg, Germany) in hybridization buﬀer at 55 C as speciﬁed by the
supplier.
2.4. Subtractive hybridization
Subtractive hybridization was performed in O41 cells using the BD
Clontech PCR-select cDNA Subtraction Kit (BD Biosciences Clon-
tech, Heidelberg, Germany) as speciﬁed by Clontech. Following the
ﬁrst round of subtraction a subsequent PCR ampliﬁcation of diﬀer-
entially expressed genes was performed, using the adapter speciﬁc
primers 1 and 2R. PCR products were then cloned into PCRII-TOPO
vector (Invitrogen, Carlsbad, USA). Selecting for the kanamycine re-
sistance gene, clones were isolated and the cDNA probes were excised
with EcoRI for Northern blot analysis.
2.5. Southwestern blotting
300 ng of each DNA sample was mounted onto a nitrocellulose
membrane (Schleicher Schuell, Germany) and crosslinked with 120 J/
m2 of UVC light. Membranes were washed twice in PBS and blocked
with 5% skim milk in PBS for 3 h. Nuclear extracts were diluted to a
protein concentration of 1 mg/ml in gel-shift buﬀer (12.5 mM Tris–HCl
pH 7.9; 3.1 mMMgCl2; 25 mM KCl, 0.5 mM DTT; 10% glycerol; 0.25
mM EDTA; 0.2 mM PMSF; 10 lg/ml leupeptin; 1 lg/ml pepstatin; 10
lg/ml aprotinin and 1 mg/ml of pGL2-Basic (Promega) plasmid DNA
for blocking) and were incubated overnight at 4 C with the mem-
brane, followed by 3 5 min washes in PBS-Tween (0.05%) [10]. The
membrane was next incubated for 1 h with antibody DO-1, followed
by 3 5 min washes in PBS-Tween. A ﬁnal incubation with a perox-
idase-conjugated secondary anti-mouse antibody and Renaissance
Enhanced Luminol Reagents (NEN, Boston, USA) was performed as
speciﬁed by the supplier.Fig. 1. Cell type-speciﬁc stimulation of CaM 2 expression in the
presence of 175H. (a) Northern blot analysis of diﬀerent 041 cultures
bulk-infected with either empty vector (V) or 175H. 18S and 28S show
rRNAs as loading controls. Right panel: Western blot analysis of 15 lg
of protein from infected 041 cultures. Calmodulin antibody was used
at 1:500; actin antibody at 1:5000. (b) Southern blot analysis of 20 lg
DNA from 041-vector and 041-175H cultures digested with EcoRI. (c)
Northern blot analysis of CaM 2 expression on the cell lines Saos-2,
H1299 and 041 infected with vector (V), 175H or 273H. (d) Northern
blot analysis of the expression of CaM 1 and 3 in 041-vector and 041-
175H cultures.3. Results
p53-negative 041 ﬁbroblasts stem from a Li-Fraumeni pa-
tient who had inherited a deletion in one p53 allele, and have
subsequently lost the remaining allele [15]. Although non-epi-
thelial, these merely immortal rather than fully transformed
cells were chosen to study gene expression changes induced by
the p53 ‘gain-of-function’ mutant 175H to minimize the chance
that 175H-inducible changes have already occurred through
other mechanisms in the course of transformation. Initially
performed cDNA microarray studies showed that, in contrast
to wt p53, 175H apparently induced only very few, and weak,
gene expression changes, in accord with the mutant being
DNA binding-impaired. Of four sequences identiﬁed to be
stimulated more than 4-fold and 13 sequences transcriptionally
overproduced at least 3-fold (the inclusion criterium), none
could be veriﬁed in Northern blot analyses. Only one sequence,
the CaM 2 gene, which was stimulated only 2.1-fold and was
therefore initially not further analyzed, could eventually also
be identiﬁed by PCR-select subtractive hybridization (see
Section 2 for details) performed with 041 cultures expressing
vector-only or 175H, and be veriﬁed in Northern and immu-
noblots.
In Northern blots, the CaM 2 transcript was 2.5-fold over-
produced in three, at diﬀerent times separately infected
175H-cultures when compared to control-infected cultures.
Concomitantly, an approximately 2-fold increase in calmodulin
protein expression became apparent in cells expressing 175H
(Fig. 1(a)). Since mutant p53 lacks important features of clas-
sical transcription factors such as a functional core DNA
binding domain, and has been documented to be able to cause
gene ampliﬁcation in human cells [6], we examined whether theCaM 2 gene dose was altered in 175H-cultures. Southern blot
analyses revealed that equal CaM 2 gene doses were present in
cultures producing 175H and in the controls (Fig. 1(b)).
Moreover, ﬂuorescence in situ hybridizations failed to show
ploidy diﬀerences between control-infected and 175H-infected
cultures (data not shown).When humanwt p53-negative Saos-2
osteosarcoma or H1299 adenocarcinoma cells were infected to
produce 175H, or when 041 cells were infected to produce the
DNA contact mutant 273H, no changes in CaM 2 gene ex-
pression were observed (Fig. 1(c)). Finally, there were no
changes in the expression of the CaM 1 and 3 genes (Fig. 1(d)).
Thus, the conformational mutant 175H can stimulate CaM 2
gene expression in a cell type-speciﬁc manner.
To examine the eﬀects of mutant p53 on the regulatory se-
quences of the CaM 2 gene, a plasmid carrying 1.1 kb of the
CaM 2 promoter, including the 50 untranslated sequences, in
front of the luciferase gene was co-transfected with either
empty vector or an eﬀector plasmid producing 175H. All
transfections included a plasmid expressing the green ﬂuores-
cence protein gene from the hCMV promoter. Luciferase ac-
tivity was analyzed 48 h after transfection, and the numbers of
transfected cells as well as the ﬂuorescence intensities were
determined by ﬂow cytometry and were employed to normalize
Fig. 2. Cell type-speciﬁc stimulation of plasmid-based CaM 2 regula-
tory sequences by 175H. (a) Transient transfections of the denoted cell
lines with the indicated reporter and eﬀector plasmids. Luciferase as-
says were performed 48 h after transfection. (b) Transfections of 041
cells with CaM 2 or Waf reporter plasmids and either wt or mutant p53
eﬀector plasmids. Error bars show SD from at least three experiments.
Fig. 3. CaM2-luc stimulation requires an intact transactivation domain
of 175H and the 50UT of the CaM 2 gene. (a) Transient transfection
for 48 h of 041 cultures with CaM2-luc reporter and eﬀector plasmids
producing 175H or variants of 175H. The Western blot, produced
from a 12% gel and stained with anti-p53 and b-actin antibodies,
documents the approximately equal expression of all used p53 eﬀector
plasmids in transient transfections. (b) Transfection for 48 h of 041
cells with the CaM2-luc reporter or a derivative lacking the 50UT, plus
either empty vector or 175H-expression plasmid.
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regulatory sequences were stimulated 2.5-fold in the presence
of 175H in 041 cells, in accord with the approximately 2-fold
CaM 2 transcript overproduction observed in 175H-expressing
041 cells. In contrast, and in agreement with the failure of
175H to stimulate CaM 2 transcript in Saos-2 and H1299 cells,
luciferase activity was not increased by 175H in these cell
types. When 041 cultures were transfected with the reporter
plasmids CaM2-luc or pWaf-luc carrying the wt p53-respon-
sive p21Waf/Cip1-promoter in front of a luc gene, and each
reporter was co-transfected either with empty vector, wt p53-
vector or 175H-expressing vector, it became apparent that
175H can stimulate the CaM 2 but notWaf promoter, while wt
p53 can transactivate Waf but not CaM 2 sequences
(Fig. 2(b)). Combined these ﬁndings indicate that the CaM 2
promoter in the context of a plasmid is stimulated in the
presence of p53 mutant 175H speciﬁcally in 041 Li-Fraumeni
cells.
To obtain information about the domains of 175H required
for CaM 2 promoter stimulation, CaM2-luc reporter plasmid
was transiently co-transfected into 041 cells with empty vector
or eﬀector plasmid expressing, at equal levels, one of the 175Hdouble mutants harboring additional defects in either the
transactivation, oligomerization or general nucleic acids
binding domains of p53 (Fig. 3(a)). The results show that the
integrity of the N-terminal transactivation domain (residues 22
and 23) is essential for CaM 2 promoter stimulation. Tetra-
merization of 175H was not absolutely required, and the C-
terminal general nucleic acids binding domain was dispensable.
Since the core DNA binding domain is dysfunctional in 175H,
the latter suggests that the eﬀect on the CaM 2 promoter does
not involve direct DNA contact by the p53 mutant. In turn,
when 041 cultures were co-transfected with CaM2-luc or
CaM2-(D50UT)-luc in which the 50UT region had been deleted,
plus the 175H expression plasmid, stimulation of luc expres-
sion was observed only with the complete CaM 2 construct
(Fig. 3(b)), indicating that the 50 untranslated sequences of the
CaM 2 gene are, directly or indirectly, targeted by 175H.
It is presently unclear how mutant p53 can modulate gene
expression. To study whether 175H associates with sequences
in the CaM 2 promoter or 50UT region, an in vitro protein-
DNA binding assay based on the Southwestern blotting
procedure was employed [10]. For this purpose, a panel of
plasmids carrying the relevant promoter sequences or not,
were immobilized on nitrocellulose membranes, incubated
with cell extracts transfected to express empty vector, wt p53
Fig. 4. In vitro-binding of p53 to plasmids with or without putative
target sequences. Cultures were transfected with either empty luc
vector, or 175H- or wt p53-producing plasmids. Expression of the
transgenes was determined by Western blotting (WB) with anti-p53
antibody DO-1. In a Southwestern blot (SWB) procedure, membranes
carrying 0.3 lg of the indicated plasmids were incubated with the ex-
tracts from the transfected cultures, and bound p53 was detected by
DO-1 diluted at 1:1000.
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mented in Fig. 4, wt p53 extracts produced a signal with the
PG13-CAT and Waf-luc plasmids but not with the luc vector,
the CaM2-luc or the CaM2-(D50UT)-luc vector, or with
MG15-CAT, indicating that wt p53 can associate with known
target sequences in this experimental setup. In contrast to wt
p53 extracts, p53-null extracts produced no signal at all. 175H
extracts generated no signal with the control vectors, and also
no signal with CaM2-luc and CaM2-(D50UT)-luc. Thus, a di-
rect binding of 175H in vitro to CaM 2 regulatory sequences in
the context of a plasmid could not be demonstrated.4. Discussion
We have presented here data indicating that the conforma-
tional p53 mutant 175H can stimulate the expression of the
CaM 2, but not the CaM 1 or 3, gene and increase the levels of
CaM protein in immortal human wt p53-null 041 Li-Fraumeni
ﬁbroblasts. 175H failed to aﬀect CaM expression in the fully
transformed human Saos-2 osteosarcoma or H1299 lung ad-
enocarcinoma cells. Furthermore, CaM 2 overexpression in
041 cells was not the result of CaM 2 gene ampliﬁcation, and
stimulation of a plasmid-based CaM 2 promoter required the
transactivation domain of 175H and the 50 untranslated se-
quences of CaM 2. Mutants of p53 have been identiﬁed as
activators of a number of cellular genes, including the multi
drug resistance (MDR)-1 [8], topoisomerase I [16], c-myc [9],
and apoptosis-inhibiting BAG-1 genes [17]. We have initially
tested, by PCR and Northern blotting, for changes in the ex-
pression of BAG-1, c-myc, the mutant p53-binding protein 1
geneMBP-1, and c-fos but have failed to observe a stimulating
eﬀect of 175H in our cell system (data not shown). So if mutant
p53 can transactivate genes, how, if at all, does it associate
with DNA? After all, the core DNA binding domain of the wt
protein is dysfunctional in the mutants. Previous ﬁnding haveindicated that mutant p53 may nonetheless be able to recog-
nize speciﬁc DNA sequences and bind these directly [18].
Furthermore, [9] could demonstrate that the c-myc gene is
regulated by mutant p53 directly, through the interaction of
the C-terminal general nucleic acids binding domain with se-
quences within exon 1 of the myc gene. Such mechanism,
however, is apparently not generally employed by mutant p53.
More recent observations have shown, for instance, that the
activation of theMDR-1 gene by mutant p53 requires bridging
between the MDR-1 promoter and mutant p53 by ETS tran-
scription factors [19]. Not least, mutant p53 may stimulate a
transcription factor that subsequently regulates a number of
downstream target genes and thus modulate gene expression
indirectly. Our ﬁnding that the C-terminus of mutant p53 is
dispensable for CaM 2 gene stimulation excludes a mechanism
like the one reported for c-myc. Finally, the combined domain
inactivation and in vitro DNA binding data render a direct
interaction between 175H and CaM 2 sequences unlikely.
Can the cell type-speciﬁc stimulation of a two-fold over-
production of the ubiquitously highly expressed CaM protein
by mutant p53 have a biological relevance? A possible clue
may come from the answer to the question why one and the
same CaM protein is encoded by three diﬀerent genes. CaM
can interact with at least 100 diﬀerent proteins, and a current
model suggests that the speciﬁcity and ﬁdelity of CaM inter-
actions may be provided by the generation of distinct subcel-
lular CaM pools, for instance through the speciﬁc transport/
local translation of diﬀerent CaM transcripts from the un-
iquely regulated CaM genes [13]. Diﬀerential localization of
CaM transcripts within cells has indeed been documented [20–
22], and selective inhibition of individual CaM genes has
yielded speciﬁc eﬀects, for example on the cell cycle and pro-
liferative capacity of cells [23–25]. The CaM 2 gene has been
suggested to be an early response gene that reacts quickly to
growth factor and hormone stimulations [26,27]. Moreover,
CaM has been associated with apoptosis and metastasis [28],
as has mutant p53 [5,29]. Future studies will show whether part
of mutant p53’s ‘gain-of-function’ activities is mediated by
calmodulin.
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